Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul 13:54:101459.
doi: 10.1016/j.gore.2024.101459. eCollection 2024 Aug.

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer

Michelle Greenman  1 , Stefania Bellone  1 , Cem Demirkiran  1 , Tobias Max Philipp Hartwich  1 , Alessandro D Santin  1
Affiliations
Case Reports

Sacituzumab govitecan in heavily pretreated, platinum-resistant high grade serous ovarian cancer

Michelle Greenman et al. Gynecol Oncol Rep. .

Abstract

Background: Treatment of recurrent platinum-resistant high grade serous ovarian cancer (HGSOC) remains a challenge. Novel treatment options for recurrent disease are an unmet need.

Case: A 69-year-old with recurrent, metastatic, platinum-resistant HGSOC overexpressing TROP2 experienced a significant response to the antibody-drug conjugate (ADC) sacituzumab govitecan after multiple failed lines of chemotherapy and targeted treatment. Following sacituzumab govitecan treatment she experienced a confirmed partial response as well as a return of CA-125 to baseline. Having now completed 8 cycles (ie, over 6 months of treatment), her disease continues to demonstrate a response to sacituzumab govitecan treatment. The ADC has been well tolerated at a dose of 10 mg/kg with no dose-limiting toxicity or need for dose reductions.

Conclusion: Sacituzumab govitecan may represent a treatment option for platinum-resistant/recurrent HGSOC that have previously failed prior lines of chemotherapy. Clinical trials with sacituzumab govitecan in platinum-resistant ovarian cancer patients are currently ongoing (https://classic.clinicaltrials.gov/ct2/show/NCT06028932).

Keywords: Antibody-drug conjugate; High grade serous ovarian cancer; Sacituzumab govitecan; TROP2.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: A.D.S. reports grants from GILEAD, grants and personal fees from MERCK, grants from BOEHINGER-INGELHEIM, grants and personal fees from Daiichi-Sankyo and grants and personal fees from EISAI and R-Pharm USA. The other authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Timeline of patient’s disease course with treatment: PD, progression of disease; SD, stable disease; PR, partial response; NED, no evidence of disease.
Fig. 2
Fig. 2
CT scans demonstrating activity of sacituzumab govitecan in high grade serous ovarian cancer. Representative abdominal wall lesion. A. CT scan 11/23/2023: B. CT scan 4/10/2024. Regression of index lesion following 4 months of sacituzumab govitecan treatment. Abdominal wall mass decreased from 3.6 cm x 1.7 cm to 3.6 x 1.0 cm.
Fig. 3
Fig. 3
CT scans demonstrating activity of sacituzumab govitecan in high grade serous ovarian cancer. Representative liver metastasis (arrow indicating location) A. CT scan 2/26/2024B. CT scan 4/10/2024. Liver metastasis completely resolved. No new or enlarging liver lesions. 3.
See this image and copyright information in PMC

References

    1. Bardia A., Messersmith W.A., Kio E.A., Berlin J.D., Vahdat L., Masters G.A., Moroose R., Santin A.D., Kalinsky K., Picozzi V., O’Shaughnessy J., Gray J.E., Komiya T., Lang J.M., Chang J.C., Starodub A., Goldenberg D.M., Sharkey R.M., Maliakal P., Hong Q., Wegener W.A., Goswami T., Ocean A.J. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann. Oncol. 2021;32 doi: 10.1016/j.annonc.2021.03.005. - DOI - PubMed
    1. Bardia A., Hurvitz S.A., Tolaney S.M., Loirat D., Punie K., Oliveira M., Brufsky A., Sardesai S.D., Kalinsky K., Zelnak A.B., Weaver R., Traina T., Dalenc F., Aftimos P., Lynce F., Diab S., Cortés J., O’Shaughnessy J., Diéras V., Ferrario C., Schmid P., Carey L.A., Gianni L., Piccart M.J., Loibl S., Goldenberg D.M., Hong Q., Olivo M.S., Itri L.M., Rugo H.S. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 2021;384 doi: 10.1056/nejmoa2028485. - DOI - PubMed
    1. Bignotti E., Zanotti L., Calza S., Falchetti M., Lonardi S., Ravaggi A., Romani C., Todeschini P., Bandiera E., Tassi R.A., Facchetti F., Sartori E., Pecorelli S., Roque D.M., Santin A.D. Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma. BMC Clin. Pathol. 2012;12 doi: 10.1186/1472-6890-12-22. - DOI - PMC - PubMed
    1. Cannistra S.A. Cancer of the Ovary. New England J. Med. 1993;329:1550–1559. doi: 10.1056/NEJM199311183292108. - DOI - PubMed
    1. Dum D., Taherpour N., Menz A., Höflmayer D., Völkel C., Hinsch A., Gorbokon N., Lennartz M., Hube-Magg C., Fraune C., Bernreuther C., Lebok P., Clauditz T.S., Jacobsen F., Sauter G., Uhlig R., Wilczak W., Steurer S., Minner S., Marx A.H., Simon R., Burandt E., Krech T., Luebke A.M. Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors. Pathobiology. 2022;89 doi: 10.1159/000522206. - DOI - PMC - PubMed

Publication types

Associated data